Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Charles River Laboratories International, Inc. announced a plasmid DNA contract development and manufacturing organization collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome, a condition with limited treatment options and no cure.